Total Payments
$9,877
2024 Payments
$2,106
Companies
30
Transactions
482
Medicare Patients
2,301
Medicare Billing
$330,758
Payment Breakdown by Category
Food & Beverage$9,665 (97.9%)
Education$211.73 (2.1%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $9,665 | 469 | 97.9% |
| Education | $211.73 | 13 | 2.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $1,654 | 68 | $0 (2024) |
| Merck Sharp & Dohme LLC | $1,320 | 70 | $0 (2024) |
| Astellas Pharma US Inc | $958.73 | 49 | $0 (2024) |
| Shionogi Inc | $874.99 | 24 | $0 (2024) |
| ViiV Healthcare Company | $847.02 | 61 | $0 (2024) |
| Insmed, Inc. | $656.66 | 34 | $0 (2024) |
| Melinta Therapeutics, LLC | $534.29 | 33 | $0 (2024) |
| La Jolla Pharmaceutical Company | $528.96 | 18 | $0 (2024) |
| Paratek Pharmaceuticals, Inc. | $460.25 | 24 | $0 (2024) |
| AbbVie Inc. | $376.15 | 15 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,106 | 92 | Gilead Sciences, Inc. ($355.16) |
| 2023 | $2,229 | 90 | Gilead Sciences, Inc. ($478.55) |
| 2022 | $1,503 | 67 | Gilead Sciences, Inc. ($497.98) |
| 2021 | $379.27 | 24 | Gilead Sciences, Inc. ($83.16) |
| 2020 | $403.63 | 17 | Allergan, Inc. ($121.96) |
| 2019 | $1,559 | 89 | Merck Sharp & Dohme Corporation ($471.54) |
| 2018 | $862.67 | 49 | Astellas Pharma US Inc ($188.75) |
| 2017 | $834.30 | 54 | The Medicines Company ($270.91) |
All Payment Transactions
482 individual payment records from CMS Open Payments — Page 1 of 20
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $24.61 | General |
| Category: Infections and Infectious Diseases | ||||||
| 12/11/2024 | La Jolla Pharmaceutical Company | XERAVA (Drug) | Food and Beverage | In-kind items and services | $27.02 | General |
| Category: TETRACYCLINE CLASS ANTIBACTERIAL | ||||||
| 12/10/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $22.93 | General |
| Category: Infectious Diseases | ||||||
| 12/09/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $21.08 | General |
| Category: Respiratory | ||||||
| 11/26/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug), ZERBAXA | Food and Beverage | In-kind items and services | $19.97 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/25/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $17.94 | General |
| Category: HIV | ||||||
| 11/20/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Orbactiv, Kimyrsa | Food and Beverage | In-kind items and services | $19.23 | General |
| Category: ANTIFUNGALS | ||||||
| 11/18/2024 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Food and Beverage | In-kind items and services | $14.42 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/08/2024 | ViiV Healthcare Company | RUKOBIA (Drug) | Food and Beverage | In-kind items and services | $19.51 | General |
| Category: HIV | ||||||
| 11/06/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $24.04 | General |
| Category: Infections and Infectious Diseases | ||||||
| 11/01/2024 | Astellas Pharma US Inc | — | Education | In-kind items and services | $39.95 | General |
| 10/29/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Orbactiv, Kimyrsa | Food and Beverage | In-kind items and services | $23.97 | General |
| Category: ANTIFUNGALS | ||||||
| 10/23/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $19.63 | General |
| Category: Infectious Diseases | ||||||
| 10/21/2024 | La Jolla Pharmaceutical Company | XERAVA (Drug) | Food and Beverage | In-kind items and services | $26.89 | General |
| Category: TETRACYCLINE CLASS ANTIBACTERIAL | ||||||
| 10/14/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $21.55 | General |
| Category: Respiratory | ||||||
| 10/09/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $17.53 | General |
| Category: ANTIBIOTIC | ||||||
| 10/02/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $20.79 | General |
| Category: Respiratory | ||||||
| 09/30/2024 | Invivyd Inc | PEMGARDA (Biological) | Food and Beverage | In-kind items and services | $26.63 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/25/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $107.39 | General |
| Category: Infections and Infectious Diseases | ||||||
| 09/24/2024 | La Jolla Pharmaceutical Company | XERAVA (Drug) | Food and Beverage | In-kind items and services | $27.02 | General |
| Category: TETRACYCLINE CLASS ANTIBACTERIAL | ||||||
| 09/23/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Orbactiv, Kimyrsa | Food and Beverage | In-kind items and services | $23.93 | General |
| Category: ANTIFUNGALS | ||||||
| 09/18/2024 | Merck Sharp & Dohme LLC | PIFELTRO (Drug), DELSTRIGO | Food and Beverage | In-kind items and services | $20.62 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/17/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $19.01 | General |
| Category: Infectious Diseases | ||||||
| 09/16/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $27.98 | General |
| 09/11/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $16.68 | General |
| Category: ANTIBIOTIC | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 611 | 27,289 | $310,205 | $84,852 |
| 2022 | 12 | 505 | 38,947 | $264,692 | $70,078 |
| 2021 | 11 | 559 | 52,641 | $341,268 | $85,673 |
| 2020 | 14 | 626 | 28,384 | $260,454 | $90,156 |
Total Patients
2,301
Total Services
147,261
Medicare Billing
$330,758
Procedure Codes
50
All Medicare Procedures & Services
50 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 119 | 480 | $92,900 | $28,375 | 30.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 54 | 181 | $41,155 | $16,261 | 39.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 80 | 85 | $33,825 | $10,532 | 31.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 45 | 76 | $17,100 | $7,091 | 41.5% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 87 | 156 | $31,200 | $6,883 | 22.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 58 | 66 | $20,700 | $6,029 | 29.1% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 13 | 17 | $9,490 | $2,810 | 29.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 28 | 39 | $6,600 | $2,320 | 35.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 11 | 11 | $3,625 | $1,388 | 38.3% |
| J1335 | Injection, ertapenem sodium, 500 mg | Office | 2023 | 29 | 122 | $18,300 | $1,233 | 6.7% |
| J0878 | Injection, daptomycin, 1 mg | Office | 2023 | 29 | 25,600 | $21,990 | $1,028 | 4.7% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 21 | 36 | $5,760 | $737.45 | 12.8% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2023 | 37 | 420 | $7,560 | $162.69 | 2.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 105 | 322 | $37,030 | $16,965 | 45.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 52 | 158 | $24,490 | $11,794 | 48.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 36 | 103 | $15,450 | $9,790 | 63.4% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 64 | 173 | $34,600 | $8,427 | 24.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 57 | 65 | $21,125 | $8,264 | 39.1% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 70 | 78 | $19,500 | $7,215 | 37.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 27 | 42 | $4,200 | $2,682 | 63.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 12 | 12 | $3,300 | $1,526 | 46.2% |
| J0878 | Injection, daptomycin, 1 mg | Office | 2022 | 20 | 37,250 | $78,225 | $1,483 | 1.9% |
| J1335 | Injection, ertapenem sodium, 500 mg | Office | 2022 | 20 | 82 | $12,300 | $1,276 | 10.4% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2022 | 12 | 18 | $2,880 | $401.26 | 13.9% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2022 | 30 | 644 | $11,592 | $252.87 | 2.2% |
About Dr. Andrea Banks, MD
Dr. Andrea Banks, MD is a Infectious Disease healthcare provider based in Lexington, Kentucky. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/03/2007. The National Provider Identifier (NPI) number assigned to this provider is 1083836399.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Andrea Banks, MD has received a total of $9,877 in payments from pharmaceutical and medical device companies, with $2,106 received in 2024. These payments were reported across 482 transactions from 30 companies. The most common payment nature is "Food and Beverage" ($9,665).
As a Medicare-enrolled provider, Banks has provided services to 2,301 Medicare beneficiaries, totaling 147,261 services with total Medicare billing of $330,758. Data is available for 4 years (2020–2023), covering 50 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Other Specialties Infectious Disease
- Location Lexington, KY
- Active Since 05/03/2007
- Last Updated 05/09/2015
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1083836399
Products in Payments
- Fetroja (Drug) $874.99
- Arikayce (Drug) $656.66
- ZERBAXA (Drug) $610.17
- Cresemba (Drug) $470.33
- NUZYRA (Drug) $460.25
- DOVATO (Drug) $410.76
- XERAVA (Drug) $377.45
- DIFICID (Drug) $349.79
- Biktarvy (Drug) $344.32
- AVYCAZ (Drug) $323.79
- Vabomere (Drug) $303.53
- VIBATIV (Drug) $257.37
- CRESEMBA (Drug) $225.94
- ISENTRESS (Drug) $184.06
- AMBISOME (Drug) $166.65
- Rezzayo (Drug) $165.64
- Mavyret (Drug) $162.97
- CABENUVA (Biological) $160.28
- XACDURO (Drug) $151.51
- TEFLARO (Drug) $132.46
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Lexington
Dr. David Dougherty, M.d, M.D
Infectious Disease — Payments: $110,300
Infectious Disease $110,300
Daniel Rodrigue, Md, MD
Infectious Disease — Payments: $50,659
Infectious Disease $50,659
Charles Rose
Infectious Disease — Payments: $42,996
Infectious Disease $42,996
Dr. Marty Allen, M.d, M.D
Infectious Disease — Payments: $39,505
Infectious Disease $39,505
John Meek, Md, MD
Infectious Disease — Payments: $13,273
Infectious Disease $13,273
Mark Dougherty, Md, MD
Infectious Disease — Payments: $12,643
Infectious Disease $12,643